August 12, 2020
Video
Given the constraints prevalent post-COVID-19, Dr Mark Fendrick, director of the University of Michigan Center for Value-Based Insurance Design, stresses that it is now more important than ever for the health care industry to prioritize payment reform, value-based benefit design, and novel policy initiatives.
August 06, 2020
Podcast
Krisda H. Chaiyachati, MD, MPH, MSHP, discusses the study he co-wrote entitled “Economic Outcomes of Insurer-Led Care Management for High-Cost Medicaid Patients.”
July 25, 2020
Article
The orders President Trump signed Friday include a deadline for the pharmaceutical industry to come up with their own plan by August 24 to lower prices.
July 22, 2020
Article
The US government partners with biotech giants Pfizer and BioNTech to distribute a coronavirus disease 2019 (COVID-19) vaccine; the COVID-19 death record continues to be broken; could Medicare be in financial trouble?
July 07, 2020
Article
End-stage renal disease has long been one of the most expensive and debilitating conditions that affects Medicare beneficiaries. Not only does dialysis cost $90,000 a year—those awaiting a kidney transplant automatically qualify for Medicare—but the need to travel to a dialysis center multiple times a week disrupts employment and home life.
July 02, 2020
Article
Significant populations of seriously ill individuals are insured by all lines of business and have meaningfully different needs and medical histories in California.
June 22, 2020
Article
Among Medicare enrollees, there was substantial between-practice variation in the use of second-generation diabetes drugs between 2007 and 2015, according to a study published in JAMA Network Open. Data also revealed a concentration of use among a few prescribers and practices, who were responsible for widespread early diffusion.
June 16, 2020
Article
The objective of this research was to identify strategies that significantly lower unnecessary inpatient utilization among Medicare beneficiaries with chronic disease.
June 14, 2020
Video
The announcement of a $35 per month out-of-pocket cap for insulin for some individuals with Medicare is a real victory for the American Diabetes Association and for people with diabetes, said Robert Gabbay, MD, PhD, chief medical and scientific officer of the American Diabetes Association.
June 12, 2020
Article
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.